Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; GDNF therapy; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; MSC-NTF; Neurotrophic factor-secreting stem cell therapy; NurOwn; NurOwn™ program one

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Autistic disorder; Huntington's disease; Multiple sclerosis; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 15 May 2017 BrainStorm Cell Therapeutics plans to access Health Canada's early access pathway with the support of Centre for Commercialization of Regenerative Medicine for treatment of patients with Amyotrophic lateral sclerosis, for authorised distribution of NurOwn® in Canada
  • 15 May 2017 BrainStorm Cell Therapeutics enters into a Memorandum of Understanding with Ichilov Hospital to make NurOwn® available to patients with Amyotrophic lateral sclerosis under Hospital Exemption regulation
  • 19 Apr 2017 Preclinical data in Autistic disorder released by BrainStorm Cell Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top